top of page

MTE International -
Biosensors International

Campobasso, Italy, 18 of December 2023. MTE International (www.mte-intl.com) is proud to announce a commercial partnership with Biosensors International (https://www.biosensors.com/intl/allegra-overview) for the distribution of interventional cardiology breakthrough technologies (TAVI System) in some Italian regions.

​

For more than 25 years, the Biosensors International Group ("Biosensors") has been designing, manufacturing and marketing innovative medical devices used during heart surgery and intensive care treatment.

AEnB2UrWTqCjzPWqVamqmOTh8R9-ilmUrRc4-amMv-c3IAclIp5IU1T3dnTnAG2DzH7ezKOUHFKXQFBvhPOJm-wMnt...ted.jpg

MTE International - Blue Medical
a Translumina Group company

Campobasso, Italy, 16th of August 2023. MTE International (www.mte-intl.com) is proud to announce a commercial partnership with BlueMedical a Translumina Group Company (https://www.wellinq.com/fabrication/protege-nc/) for the distribution of interventional cardiology breakthrough technologies in some Italian regions.BlueMedical, established in 2013, manufactures balloon catheters, including drug-coated baloons (DCB) along with other speciality balloons for complex coronary interventions.BlueMedical has developed Protégé NC and Protégé DCB catheters to better overcome current DCB technologies, as well as to provide high safety and efficacy. Protégé technology avoids any drug loss during the device advancement to lesion, helping to deliver a high drug concentration at the targeted site.

Protege_sqr.png

MTE International - MC Health

Campobasso, Italy, 1st of August 2022. MTE International (www.mte-intl.com) is proud to announce a commercial partnership with MC Health S.r.l (www.mchealth.it) for the distribution of interventional cardiology breakthrough technologies in Molise Region.

 

MC Health is the national distributor for OrbusNeich (www.orbusneich.com) of their range of innovative devices including an extensive portfolio of high-performance balloons (Sapphire family, Jade Family), speciality catheters (Scoreflex), microcatheters (Teleport and Teleport Control) and the orbital atherectomy system from C.S.I. (Diamondback 360 and Stealth 360) https://orbusneich.com/product/diamondback-360/ , https://orbusneich.com/product/stealth-360/ 

bgImage

 

MTE International - MeMed

Campobasso, Italy, 1st of December 2021. MTE International (www.mte-intl.com) is proud to announce a commercial partnership with MeMed (www.memed.com) for the distribution in Italy of a breakthrough innovative technology: MeMed Covid-19 Severity™ on MeMed Key®.

MeMed COVID-19 Severity is a pioneering host-response technology that decodes signals of the immune system to accurately determine whether SARS-Cov-2 patients are likely to have a severe outcome. It does so by measuring multiple proteins from a serum sample and applying a machine-learning algorithm to stratify a patient's risk to experience a severe outcomes.

The test runs in 15 minutes on the company’s point-of-need platform, MeMed Key.®. The test aims to help physicians identify who may benefit from escalated care, and who can be safely discharged from hospital and to self-isolate at home. MeMed COVID-19 Severity™ has a CE Mark in Europe.

original (4)_edited_edited.png
bgImage

MTE International - Translumina GmbH

Campobasso, Italy, 30th of April 2021. MTE International (www.mte-intl.com) is proud to announce a commercial partnership with Translumina GmbH (www.translumina.com) for the distribution of interventional cardiology breakthrough technologies in Abruzzo, Marche, Molise & Umbria regions.

VIVO ISAR Stent: an innovative technology which eliminates the use of Polymer by using Dual Drug Technology: Sirolimus and Probucol. 

10 years follow up clinical data of safety and efficacy in 3002 patients is published in Journal of American College of Cardiology. At 10 year clinical outcomes of stent thrombosis from RCTs in Patients with Coronary Artery Disease, VIVO ISAR demonstrated lower definite/ probable stent thrombosis rate than Xience (ISAR TEST-4) and Resolute.

Yukon Drug Eluting Stent is recomm​ended by the latest European Society of Cardiology (ESC) guidelines for myocardial revascularization.

"Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease Results From the ISAR-TEST 4 Randomized Trial"

Circulation -2018.

In this unique long term analysis at 10 years, Yukon has shown the lowest rate of Definite/ Probable Stent Thrombosis with a significant risk reduction than Cypher (50%) and numerically lower TLR rates as compared to Xience (29%) while maintaining the similar efficacy.

bgImage

MTE International - Dianosic

Campobasso, Italy, 7th of April 2021. MTE International (www.mte-intl.com) is proud to announce a commercial partnership with dianosic (www.dianosic.com) for the distribution of CAVI-T , a Breakthrough innovative technology for ENT diseases, for the entire Italian territory. 

Dianosic works with healthcare professionals to provide life-changing solutions for patients in the management of intranasal bleeding (epistaxis) and chronic sinusitis. This start-up is part of the selection of Challenges "100 start-ups to invest in 2021.

Intranasal bleeding is very common, costly and has a negative impact on patient’s quality of life. This is particularly noticeable in Chronic cases, epistaxis also greatly impacts care givers quality of life. The “disease” incidence is increasing due to population ageing and exacerbated by the growth of the number of patients suffering from cardiovascular diseases and being treated with anticoagulants.




bottom of page